LINEAR ALKYLBENZENE SULFONATE (LAS) - UNEP Chemicals

OECD SIDS LINEAR ALKYLBENZENE SULFONATE (LAS)
Test substance: C10-14 LAS, sodium salt; activity: 98.1% on an anhydrous basis (41.9%
active)
Reference: Buehler, E.V., Newmann, E.A., and King, W.R. 1971. Two year feeding
and reproduction study in rats with linear alkylbenzene sulfonate (LAS).
Toxicol. Appl. Pharmacol. 18:83-91.
Reliability: 2 Valid with restrictions
(l)
Species/strain: Rat/Wistar
Sex: Female [ ]; Male [X]; Male/Female [ ]; No data [ ]
Administration: Drinking water
Exposure period: 2 years
Frequency of treatment: Daily
Doses: 0.01%, 0.05%, 0.1% (20,100, 200 mg/kg bw d)
Control group: Yes [X]; No [ ]; No data [ ];
Concurrent no treatment [X]; Concurrent vehicle [ ]; Historical [ ]
Results: There were no changes due to the administration of LAS in regard to growth,
mortality, the weight of major organs, or histopathological findings. The
intake of LAS was about 200 mg/kg bw d in the 0.1% group.
Method: Groups of 20 male Wistar rats were given LAS in drinking water daily for 2
years.
GLP: Yes [ ] No [X] ? [ ]
Test substance: LAS, activity: 34.55%
Remarks: Information as cited in the IPCS document.
Reference: 1) European Commission. 2000a. Benzenesulfonic acid, C10-13-alkyl derivs.,
sodium salts. Year 2000 CD-ROM edition.
2) Tiba, S. 1972. Studies on the acute and chronic toxicity of linear
alkylbenzene sulfonate. J. Food Hyg. Soc. Jpn. 16:66-71 (in Japanese); cited
in: IPCS (1996); Environmental Health Criteria 169: Linear Alkylbenzene
Sulfonates (LAS) and Related Compounds. WHO, Geneva, Switzerland.
Reliability: 4 This study is assigned a reliability score of 4 because the original report
was not available for review. However, the study was evaluated by IPCS
prior to inclusion in their criteria document.
(m)
Species/strain: Rhesus monkey (Macaca mulatta)
Sex: Female [ ]; Male [ ]; Male/Female [X]; No data [ ]
Administration: Simultaneous oral and subcutaneous
Exposure period: 28 days
Frequency of treatment:daily
Dose: 30, 150, 300 mg/kg/day oral via gavage given simultaneously with 0.1, 0.5,
1.0 mg/kg/day subcutaneous administration
Control group: Yes [X]; No [ ]; No data [ ];
Concurrent no treatment [X]; Concurrent vehicle [ ]; Historical [ ]
NOAEL: 150 mg/kg/day (oral) with 0.5 mg/kg/day (sc)
Results: At 300 (oral) and 1.0 (sc) mg/kg/day, the monkeys vomited frequently and
usually within 3 hours of administration. An increased frequency of loose or
liquid faeces was recorded for animals receiving 150 (oral) and 0.5 (sc)
mg/kg. These effects are probably related to the inherent irritative effects of
LAS rather than its systemic toxicity. Fibrosis of the injection sites was
found among all the test group, the incidence and severity being dose related.
Ophthalmoscopy, laboratory examination of blood and urine, organ weight
analysis and histopathological investigation did not detect any further
treatment-related responses.
Method: Three male and 3 female monkeys were given simultaneous oral and
subcutaneous administration doses daily for 28 days. Animals were observed
UNEP PUBLICATIONS 278